Bristol-Myers Squibb has formed an R&D partnership with GentiBio, aimed at developing regulatory T cel (Treg) therapies for inflammatory bowel disease (IBD). The deal includes an undisclosed upfront ...

The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two decades. Historically, therapeutic strategies primarily focused on suppressing ...

Inflammatory bowel disease is a chronic condition of unknown origin characterized by severe inflammation and mucosal destruction in the intestine. There are two main forms: Crohn s disease, which can ...

Objective The role of the brain–gut axis is of increasing interest in IBD, as the link between common mental disorders and GI inflammation may be bidirectional. We performed a systematic review ...